What is Versidep (Flupenthixol/Melitracen)?
Versidep is a fixed-dose combination tablet containing flupenthixol 0.5 mg (a first-generation antipsychotic) and melitracen 10 mg (a tricyclic antidepressant with noradrenaline/serotonin reuptake inhibition properties), primarily used for treating depression, anxiety, and various functional somatic disorders.
Pharmacological Components
Flupenthixol (0.5 mg)
- Drug class: First-generation (typical) antipsychotic, specifically a trifluoromethyl phenothiazine derivative 1
- Mechanism: Dopamine receptor antagonist with anxiolytic properties at low doses 2
- At the low dose used in this combination, it provides anti-anxiety effects without the significant antipsychotic side effects seen at higher doses
Melitracen (10 mg)
- Drug class: Tricyclic antidepressant
- Mechanism: Noradrenaline and serotonin reuptake inhibitor with antidepressant and anxiolytic properties 2
- Function: Provides mood elevation and reduces depressive symptoms
Clinical Applications
The combination has demonstrated efficacy in multiple conditions:
Primary Indications
- Depression and anxiety disorders - The synergistic combination addresses both mood and anxiety symptoms 2
- Functional dyspepsia - Showed 73.9% symptom relief vs. 26.1% with placebo, with significant quality of life improvement (p=0.03) 3
- Refractory chronic cough - Achieved 65.3% cough resolution rate vs. 32% with placebo (p=0.0009) in patients unresponsive to neuromodulators 4
- Persistent idiopathic facial pain - 82% of patients achieved ≥50% pain reduction, with median onset of 3 days 5
- Aerophagia - Significant improvement in symptom scores compared to prokinetic therapy alone 6
- Epigastric pain syndrome - Particularly in female patients with somatization symptoms 7
Dosing and Administration
Standard dosing: 1 tablet twice daily (morning and noon), containing flupenthixol 0.5 mg + melitracen 10 mg per tablet 2, 4
- Treatment duration: Typically 2-4 weeks for initial assessment, with some conditions requiring longer therapy 5, 4
- Onset of action: Median 3 days for pain conditions 5
- Bioavailability: Demonstrated bioequivalence between formulations under both fasted and fed conditions 2
Safety Profile
Common Adverse Effects (Generally Mild)
The combination is generally well-tolerated with adverse event rates of approximately 51% vs. 34% for placebo 4:
- Drowsiness and sedation
- Dizziness
- Dry mouth
- Mild gastrointestinal symptoms
- All adverse events were mild and resolved after discontinuation 4
Important Precautions
Extrapyramidal symptoms (EPS): While flupenthixol is a first-generation antipsychotic, the low dose (0.5 mg) used in this combination minimizes EPS risk. However, avoid in patients with Parkinson's disease or dementia with Lewy bodies due to dopamine antagonism 8
Cardiovascular considerations:
- May cause orthostatic hypotension 8
- Potential QTc prolongation (typical of phenothiazines) 8
- Monitor in elderly or frail patients
Drug interactions:
- Avoid combining with MAOIs due to serotonin syndrome risk 9
- Caution with other serotonergic medications
- CYP450 interactions possible with melitracen component 10
Contraindications:
- Severe liver disease
- Myasthenia gravis
- Severe pulmonary insufficiency
- Concurrent MAOI use
Clinical Considerations
When to Use
This combination is particularly valuable for:
- Patients with functional somatic disorders where psychological factors contribute to physical symptoms
- Depression/anxiety with prominent somatic complaints
- Conditions unresponsive to standard first-line therapies (e.g., refractory chronic cough after neuromodulator failure) 4
- Functional gastrointestinal disorders with inadequate response to acid suppression 3
Monitoring Requirements
- Assess response within 1-2 weeks of initiation
- Monitor for sedation, especially during first week
- Check vital signs for orthostatic hypotension in elderly patients
- Evaluate for extrapyramidal symptoms, though rare at this dose
- No serious adverse events or treatment-related deaths reported in clinical trials 4
Key Advantages
- Rapid onset: Symptom improvement often within days 5
- Dual mechanism: Addresses both mood and somatic symptoms simultaneously
- Good tolerability: Low discontinuation rates due to adverse effects
- Broad applicability: Effective across multiple functional disorders with psychological components
The combination represents a unique therapeutic option that bridges psychiatric and somatic medicine, particularly valuable when standard treatments fail and somatization is suspected.